{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Course 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"23.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Course 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"},{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Course 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG001","value":"20.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Course 6 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"Cell-free DNA based assay was used to determine whether H3F3A K27M mutation could be detected in patients' blood samples. Percentage of patients in whom this mutation was detected was summarized within each stratum and at each time point.","groups":[{"description":"Recurrent or progressive DIPG patients who were treated with the \"3 times/week, three weeks on, one week off\" schedule","id":"OG000","title":"Stratum 1"},{"description":"Non-progressed DIPG or H3K27M+ thalamic DMG patients who were treated with the \"3 times/week, every other week\" schedule","id":"OG001","title":"Stratum 2"}],"paramType":"NUMBER","populationDescription":"Only patients with cell-free DNA assay results available from blood samples were included in this analysis. Per the statistical section in the protocol, percentage of patients in whom the mutation was detected was summarized within each stratum and at each time point.","reportingStatus":"POSTED","timeFrame":"Blood samples were collected for cell-free DNA based assay at Course 1 Day 1 (C1D1), C2D1, C4D1, and C6D1.","title":"Percentage of Patients With H3F3A K27M Mutation Detected in Blood Samples","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}